comparemela.com

Latest Breaking News On - Institutional investors weigh in on rocket pharmaceuticals - Page 4 : comparemela.com

Equities Analysts Offer Predictions for Rocket Pharmaceuticals, Inc s Q1 2023 Earnings (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating) – William Blair issued their Q1 2023 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a note issued to investors on Wednesday, March 22nd. William Blair analyst S. Corwin forecasts that the biotechnology company will post earnings of ($0.96) per share for the quarter. William Blair has […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Outperform Rating from William Blair

William Blair restated their outperform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) in a research report report published on Wednesday, PriceTargets.com reports. Several other equities research analysts have also issued reports on the company. StockNews.com assumed coverage on Rocket Pharmaceuticals in a research report on Thursday, March 16th. They set a sell […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Down After Earnings Miss

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating) gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $18.46, but opened at $17.81. Rocket Pharmaceuticals shares last traded at $18.85, with a volume of 71,606 shares traded. The biotechnology company reported ($0.92) EPS for the […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.